Richard D. Carvajal, MD: The other big category of toxicity is the cytokine release syndrome [CRS]-type symptoms.
2021
FDA Grants Fast Track Designation to Nemvaleukin Alfa for Mucosal Melanoma
Nemvaleukin alfa (Nemvaleukin) has been granted fast-track designation by the FDA for the treatment of patients with mucosal melanoma who have received prior treatment with an anti–PD-L1 therapy, according to a press release from Alkermes.1
FDA Sets PDUFA Date for Pembrolizumab
Merck announced that its phase 3 KEYNOTE-716 (NCT03553836) trial investigating pembrolizumab (Keytruda) has met its primary endpoint…
UNLV professor’s cancer surgery delayed due to hospital bed shortage
UNLV law professor Michael Kagan was supposed to have surgery last week to remove cancerous lymph nodes from his neck.